Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Closed 06-26 16:00:00 EDT

632.90

+12.76

+2.06%

盘后633.09

+0.19+0.03%

19:57 EDT

High638.76	Low623.44	Vol1.21M
Open623.64	D1 Closing620.14	Amplitude2.47%
Mkt Cap66.91B	Tradable Cap65.38B	Total Shares105.72M
T/O768.57M	T/O Rate1.17%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":632.9,"timestamp":1782504000000,"preClose":620.14,"halted":0,"volume":1213632,"hourTrading":{"tag":"盘后","latestPrice":633.09,"preClose":632.9,"latestTime":"19:57 EDT","volume":91484,"amount":57899197.77995,"timestamp":1782518247787,"change":0.19,"changeRate":0.0003,"amplitude":0.001754},"delay":0,"changeRate":0.02057599896797496,"floatShares":103302739,"shares":105719806,"eps":41.06084,"marketStatus":"Closed","change":12.76,"latestTime":"06-26 16:00:00 EDT","open":623.64,"high":638.76,"low":623.44,"amount":768568630.2336,"amplitude":0.024704,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.06084,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":620.14,"dividendRate":0.005751,"preHourTrading":{"tag":"盘前","latestPrice":625.53,"preClose":620.14,"latestTime":"09:29 EDT","volume":116,"amount":72195.27380000001,"timestamp":1782480579163,"change":5.39,"changeRate":0.008692,"amplitude":0.020963},"postHourTrading":{"tag":"盘后","latestPrice":633.09,"preClose":632.9,"latestTime":"19:57 EDT","volume":91484,"amount":57899197.77995,"timestamp":1782518247787,"change":0.19,"changeRate":0.0003,"amplitude":0.001754},"volumeRatio":0.863153,"impliedVol":0.3249,"impliedVolPercentile":0.2112},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2646801398","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2646801398","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646801398?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:45","pubTimestamp":1782506700,"startTime":"0","endTime":"0","summary":"DJ Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rallied 2.06% to $632.90 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.05% to 7,354.02 and Dow Jones Industrial Average  falling 0.09% to 51,876.11.Regeneron Pharmaceuticals Inc. closed 22.92% short of its 52-week high of $821.11, which the company reached on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Amgen Inc.  rose 1.56% to $358.33, Moderna Inc.  rose 12.59% to $67.27, and Gilead Sciences Inc.  rose 3.26% to $127.88.Trading volume  eclipsed its 50-day average volume of 1.0 M.Data source: Dow Jones Market Data, FactSet. Data compiled June 26, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. Ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646367555","title":"How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2646367555","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646367555?lang=en_us&edition=fundamental","pubTime":"2026-06-27 03:16","pubTimestamp":1782501384,"startTime":"0","endTime":"0","summary":"Earlier this week, Regeneron Pharmaceuticals reported that both the FDA and EMA accepted regulatory applications for cemdisiran to treat anti‑AChR antibody‑positive generalized myasthenia gravis, with the FDA granting Priority Review and a target action date in November 2026.\nIf approved, cemdisiran could become the first siRNA therapy for gMG and the only option given subcutaneously just four times a year, potentially easing treatment burden for patients who often struggle with chronic...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/how-investors-may-respond-to-regeneron-pharmaceuticals-regn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/how-investors-may-respond-to-regeneron-pharmaceuticals-regn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU2089984988.USD","ARTY","BK4588","ISBC","LU0823434740.USD","LU2362541513.USD","LU1917777945.USD","LU0823434583.USD","LU1974910355.USD","LU2362541273.HKD","BK4211","CHAT","LU0882574055.USD","LU2468319806.SGD","LU0114720955.EUR","LU0320765992.SGD","LU2106854487.HKD","LU0058720904.USD","LU0053666078.USD","BK4585","AGIX","LU0109394709.USD","LU2023250504.SGD","LU0289739699.SGD","AIPO","LU2237438978.USD","LU0889565916.HKD","LU0823416689.USD","LU2362540622.SGD","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646856413","title":"Regeneron Updates Financial Calendar for Second-quarter Results Release and Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2646856413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646856413?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:05","pubTimestamp":1782417918,"startTime":"0","endTime":"0","summary":"Regeneron updates financial calendar for second-quarter results release and conference callRegeneron schedules release of Q2 2026 financial and operating results on July 30, 2026, before the US market","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL158mhL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2106854487.HKD","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2362541273.HKD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2468319806.SGD","LU2362540622.SGD","BK4139","LU0053666078.USD","LU0889565916.HKD","NDAQ","SG9999014005.SGD","SG9999014039.USD","SG9999014013.SGD","LU0823434740.USD","LU0320765992.SGD","REGN","BK4112","BK4585","LU1917777945.USD","IE00B64PRP62.GBP","SG9999014021.USD","IE00BN0W2W23.USD","LU0289739699.SGD","LU0114720955.EUR","LU0109394709.USD","LU2237438978.USD","LU1974910355.USD","LU0823416689.USD","LU2362541513.USD","LU2095319765.USD","BK4588","LU2210149790.SGD","LU0882574055.USD","LU0058720904.USD","IE00BGHQF748.EUR","LU2089984988.USD","LU0823434583.USD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646802032","title":"Regeneron’s New First-in-Human Eczema Drug REGN20423: Early Trial Progress and Investor Takeaways","url":"https://stock-news.laohu8.com/highlight/detail?id=2646802032","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646802032?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:31","pubTimestamp":1782405089,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals, Inc. (REGN) is running a first-in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regenerons-new-first-in-human-eczema-drug-regn20423-early-trial-progress-and-investor-takeaways?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regenerons-new-first-in-human-eczema-drug-regn20423-early-trial-progress-and-investor-takeaways?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","LU0320765992.SGD","LU0289739699.SGD","LU2237438978.USD","LU0882574055.USD","REGN","LU2362541273.HKD","LU0823416689.USD","LU0823434583.USD","LU1917777945.USD","LU2362540622.SGD","BK4588","LU0114720955.EUR","BK4585","LU2468319806.SGD","BK4097","LU2023250504.SGD","LU2089984988.USD","PRGS","LU0889565916.HKD","LU2065732104.USD","LU2106854487.HKD","LU0823434740.USD","LU0109394709.USD","LU1974910355.USD","LU0053666078.USD","LU2362541513.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646187741","title":"Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2646187741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646187741?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:49","pubTimestamp":1782388192,"startTime":"0","endTime":"0","summary":"BUZZ-Kymera rises on accelerated trial timeline for experimental eczema drug** Shares of drug developer Kymera TherapeuticsKYMR.Orise 7.8% to $107.8 premarket** Co says it has completed enrollment for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nL4N42X14L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","LU1496350171.SGD","LU1548497426.USD","LU0109394709.USD","LU2213496289.HKD","LU0859254822.USD","LU2237443465.HKD","LU1974910355.USD","LU1668664300.SGD","LU1670627923.USD","LU0820562030.AUD","IE00BLSP4239.USD","LU0882574055.USD","LU2211815571.USD","JPMO","LU0976567544.SGD","IE00BFXG1179.USD","LU0211328371.USD","LU0345770993.USD","LU2462157665.USD","JPO","LU0320765489.SGD","LU0070302665.USD","LU1084165304.USD","LU0868494617.USD","LU2552382215.SGD","BK4139","LU0868494708.USD","LU2756315664.SGD","LU1914381329.SGD","LU2237443895.HKD","IE00B775SV38.USD","LU1145028129.USD","LU0889565916.HKD","LU2746668461.USD","REGN","JPX","IE0034235303.USD","IE00BDRTCR15.USD","LU2237443382.USD","KYMR","LU0323591593.USD","LU2756315318.SGD","IE00B1BXHZ80.USD","LU2054465674.USD","LU1116320901.HKD","LU0640476718.USD","LU2023250843.SGD","LU2362541513.USD","IE00B1XK9C88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645248690","title":"AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2645248690","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645248690?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:50","pubTimestamp":1782129000,"startTime":"0","endTime":"0","summary":"If approved, the drug would be a new option for people with atopic dermatitis. AbbVie is buying Apogee Therapeutics, which is developing a long-acting treatment for atopic dermatitis.AbbVie is acquiring a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash.The acquisition would be for Apogee Therapeutics, which is working on a long-acting treatment for atopic dermatitis that's set to move into Phase 3 trials later this year. The drug works by blocking IL-13, the protein that causes eczema.If approved, the drug would compete with Dupixent, an IL-4 and IL-13 inhibitor that is used to treat numerous inflammatory conditions like atopic dermatitis and chronic obstructive pulmonary disease, or COPD. That medicine, which is sold by Regeneron Pharmaceuticals  and Sanofi , is one of the world's top-selling drugs.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","LU0109394709.USD","IE00BDGV0183.EUR","SG9999015945.SGD","REGN","LU0861579265.USD","LU1093756168.USD","LU0823434740.USD","LU1037948541.HKD","IE00BLSP4452.SGD","APGE","LU0310800379.SGD","LU0949170772.SGD","LU0738911758.USD","LU2087621335.USD","LU2362541513.USD","LU0868494617.USD","LU1934455863.HKD","LU0943347566.SGD","LU1267930573.SGD","LU1162221912.USD","IE00BFTCPJ56.SGD","LU2237443895.HKD","IE000MB6IJN5.SGD","LU1989772923.USD","IE00B19Z3B42.SGD","LU1670627923.USD","LU0289739699.SGD","LU0057025933.USD","LU0122379950.USD","LU1934455194.USD","LU0053671581.USD","BK4588","LU0868494708.USD","LU1929549753.HKD","SG9999015978.USD","LU0234572021.USD","LU0942090050.USD","LU0124676726.USD","LU1074936037.SGD","LU0128525929.USD","LU0211328371.USD","LU2129689431.USD","LU2237438978.USD","ABBV","LU0820561909.HKD","LU1057294990.SGD","IE0004445239.USD","LU0965508806.USD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645141021","title":"Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2645141021","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645141021?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:33","pubTimestamp":1782127980,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals said U.S. and European regulators have accepted its applications seeking approval of its cemdisiran drug candidate in the rare and chronic autoimmune disease generalized myasthenia gravis, or gMG.Regeneron on Monday said the U.S. Food and Drug Administration and the European Medicines Agency will review cemdisiran to for adults with gMG who are anti-acetylcholine receptor antibody-positive.The Tarrytown, N.Y., biotechnology company said the FDA has granted the application priority review, which shortens the review period, and that it set a target action date in November.Regeneron, which is developing cemdisiran under a licensing agreement with Alnylam Pharmaceuticals, said it expects a decision from the European Commission in the second half of 2027.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","LU2106854487.HKD","LU0289739699.SGD","LU0823434583.USD","LU2468319806.SGD","BK4139","LU2023250504.SGD","LU0053666078.USD","LU0882574055.USD","LU1974910355.USD","LABU","LU0320765992.SGD","LU2362541273.HKD","LU2237438978.USD","LU2362540622.SGD","LU0058720904.USD","LU0114720955.EUR","ALNY","LU0109394709.USD","LU0823434740.USD","BK4585","LU2362541513.USD","LU0889565916.HKD","BK4081","BK4588","LU0823416689.USD","LU1917777945.USD","LU2089984988.USD","BK4548","REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029935","title":"Regeneron says FDA accepts cemdisiran gMG filing for priority review","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029935","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029935?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126059,"startTime":"0","endTime":"0","summary":"Regeneron’s FDA application for cemdisiran in anti-AChR antibody-positive generalized myasthenia gravis was accepted under Priority Review.FDA target action date set for November 2026, supported by a Priority Review Voucher.EMA also validated the filing; a European Commission decision is expected in the second half of 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL9dkh2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","LU0320765992.SGD","REGN","IE00BKPKM429.USD","SG9999014013.SGD","LU2095319765.USD","LU1917777945.USD","LU2468319806.SGD","IE00BN0W2T93.GBP","LU0109394709.USD","LU2089984988.USD","LU2106854487.HKD","LU2362540622.SGD","LU0053666078.USD","IE00B3QW5Z07.USD","LU1974910355.USD","NDAQ","LU2210149790.SGD","BK4588","LU0314104364.USD","BK4112","SG9999014021.USD","LU0823434583.USD","LU0882574055.USD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","LU0058720904.USD","LU0823416689.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU2023250504.SGD","BK4139","LU2362541273.HKD","LU0823434740.USD","LU0114720955.EUR","LU0289739699.SGD","LU0889565916.HKD","LU2362541513.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645951029","title":"Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645951029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645951029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2BRBYY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1974910355.USD","LU0823434740.USD","LU0109394709.USD","BK4139","LU0058720904.USD","LU2362541513.USD","LU0823434583.USD","LU0053666078.USD","LU2023250504.SGD","LU0882574055.USD","LU2362541273.HKD","LU1917777945.USD","LU2106854487.HKD","LU2089984988.USD","LU0320765992.SGD","LU0889565916.HKD","LU2362540622.SGD","LU2468319806.SGD","LU0289739699.SGD","LU2237438978.USD","LU0114720955.EUR","BK4585","REGN","LU0823416689.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645802995","title":"Regeneron Pharmaceuticals - European Commission Decision on Cemdisiran Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2645802995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645802995?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2BRBYY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0823416689.USD","LU0114720955.EUR","LU2023250504.SGD","LU0289739699.SGD","LU2237438978.USD","LU0109394709.USD","BK4585","LU0882574055.USD","LU1917777945.USD","LU2362540622.SGD","LU0320765992.SGD","LU0053666078.USD","LU2362541513.USD","LU0889565916.HKD","LU2106854487.HKD","LU2362541273.HKD","LU2468319806.SGD","LU0058720904.USD","BK4139","LU2089984988.USD","LU0823434583.USD","REGN","BK4588","LU1974910355.USD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645622029","title":"Cemdisiran Regulatory Submissions Accepted for Review by FDA and Ema for the Treatment of Generalized Myasthenia Gravis (Gmg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645622029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645622029?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2BRBYY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2362541513.USD","LU0114720955.EUR","LU2362540622.SGD","BK4139","LU2023250504.SGD","LU0823434583.USD","LU2468319806.SGD","LU2106854487.HKD","LU0320765992.SGD","LU0882574055.USD","LU0823434740.USD","LU1917777945.USD","LU0289739699.SGD","LU2237438978.USD","LU0109394709.USD","LU0053666078.USD","LU2362541273.HKD","LU0823416689.USD","LU0058720904.USD","LU1974910355.USD","BK4588","REGN","LU0889565916.HKD","BK4585","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029952","title":"Regeneron Pharmaceuticals - Plans Regulatory Filing for Cemdisiran in Japan in Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029952?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA2BRBYY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0058720904.USD","BK4139","LU2089984988.USD","LU0889565916.HKD","LU0053666078.USD","LU2106854487.HKD","LU0823416689.USD","LU0109394709.USD","BK4585","REGN","LU0289739699.SGD","LU2468319806.SGD","LU2362540622.SGD","LU2362541513.USD","BK4588","LU1974910355.USD","LU2023250504.SGD","LU0823434583.USD","LU1917777945.USD","LU2362541273.HKD","LU0320765992.SGD","LU2237438978.USD","LU0882574055.USD","LU0823434740.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021109","title":"Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021109","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021109?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126000,"startTime":"0","endTime":"0","summary":"Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315167/0/en/Cemdisiran-Regulatory-Submissions-Accepted-for-Review-by-FDA-and-EMA-for-the-Treatment-of-Generalized-Myasthenia-Gravis-gMG.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4081","LU2468319806.SGD","LU2106854487.HKD","LU0053666078.USD","LU2237438978.USD","BK4588","EMA","LU2362540622.SGD","LU0823416689.USD","LU1974910355.USD","LU2362541273.HKD","LU1917777945.USD","REGN","LU0320765992.SGD","LU0823434740.USD","BK4585","LABU","LU0882574055.USD","LU2362541513.USD","LU2023250504.SGD","LU2089984988.USD","LU0109394709.USD","BK4139","LU0114720955.EUR","LU0058720904.USD","LU0823434583.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409366","title":"AbbVie would gain an experimental eczema drug by buying biotech: report","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409366","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645409366?lang=en_us&edition=fundamental","pubTime":"2026-06-21 00:11","pubTimestamp":1781971860,"startTime":"0","endTime":"0","summary":"If approved, the drug would be a new option for people with atopic dermatitis. AbbVie is reportedly nearing a deal to buy Apogee Therapeutics, which is developing a long-acting treatment for atopic dermatitis.AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.The acquisition would be for Apogee Therapeutics , which is working on a long-acting treatment for atopic dermatitis that's set to move into Phase 3 trials later this year. The drug works by blocking IL-13, the protein that causes eczema.If approved, the drug would compete with Dupixent, an IL-4 and IL-13 inhibitor that is used to treat numerous inflammatory conditions like atopic dermatitis and chronic obstructive pulmonary disease, or COPD. That medicine, which is sold by Regeneron Pharmaceuticals  and Sanofi , is one of the world's top-selling drugs.This content was created by MarketWatch, which is operated b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0456855351.SGD","LU2237443978.SGD","LU2129689431.USD","LU0859254822.USD","REGN","LU1934455277.USD","APGE","LU0109394709.USD","LU1093756325.SGD","LU0098860793.USD","SG9999015986.USD","LU2133065610.SGD","LU2237438978.USD","LU1974910355.USD","LU0289961442.SGD","LU0912757837.SGD","LU1551013425.SGD","LU1430594728.SGD","LU2347655156.SGD","SG9999015952.SGD","SG9999015945.SGD","IE0000B7K699.USD","LU0689626769.HKD","LU0965508806.USD","LU1585245621.USD","IE00B2B36J28.USD","LU0889565916.HKD","ABBV","LU1244550494.USD","LU2023250504.SGD","LU1670628061.USD","IE00BGHQF631.EUR","LU1037948897.HKD","LU1267930490.SGD","LU0949170772.SGD","LU2362540622.SGD","IE000BZT7R73.USD","LU0069063385.USD","LU1093756168.USD","LU1839511570.USD","IE00B19Z3B42.SGD","IE00BDGV0183.EUR","LU0053666078.USD","LU1934455194.USD","LU1291159041.SGD","LU0211328371.USD","IE00BJT1NW94.SGD","LU0432979614.USD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644721050","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2644721050","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644721050?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:46","pubTimestamp":1781729160,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  shed 1.11% to $607.93 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 1.21% to 7,420.10 and Dow Jones Industrial Average  falling 0.98% to 51,492.55.This was the stock's second consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 25.96% short of its 52-week high of $821.11, which the company reached on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc.  fell 1.78% to $341.66, Moderna Inc.  rose 11.55% to $61.80, and Gilead Sciences Inc.  fell 1.40% to $125.45.Trading volume  eclipsed its 50-day average volume of 955,366.Data source: Dow Jones Market Data, FactSet. Data compiled June 17, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published ind","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644729461","title":"Regeneron Pharmaceuticals shareholders elect Class II directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644729461","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644729461?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:07","pubTimestamp":1781726833,"startTime":"0","endTime":"0","summary":"Regeneron held its annual shareholder meeting on June 12, 2026.Shareholders selected five Class II director nominees to serve until the 2027 annual meeting.PwC’s appointment as independent registered public accounting firm for the year ending Dec. 31, 2026 was ratified.An advisory resolution backing executive pay was adopted; it does not itself implement any pay actions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLjSGTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0882574055.USD","REGN","LU0823434583.USD","LU0114720955.EUR","LU1917777945.USD","LU0823434740.USD","LU2237438978.USD","BK4588","LU2089984988.USD","LU0289739699.SGD","LU0109394709.USD","LU2023250504.SGD","LU2362541273.HKD","LU2106854487.HKD","LU0320765992.SGD","LU2468319806.SGD","LU0053666078.USD","BK4139","LU0058720904.USD","LU0889565916.HKD","LU2362541513.USD","BK4585","LU2362540622.SGD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643143982","title":"Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations","url":"https://stock-news.laohu8.com/highlight/detail?id=2643143982","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643143982?lang=en_us&edition=fundamental","pubTime":"2026-06-13 16:29","pubTimestamp":1781339349,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) is back in focus after the World Health Organization recommended its antibody therapy maftivimab for Ebola trials, along with renewed attention on its wider R&D platform and expanding collaborations.\nSee our latest analysis for Regeneron Pharmaceuticals.\nDespite the recent WHO spotlight on maftivimab and expanded oncology collaborations, the stock has lost momentum. The 30-day share price return is down 14.97% and the year-to-date share price return is down...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-stock-valuation-after-who-ebola-trial-backing","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-stock-valuation-after-who-ebola-trial-backing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2468319806.SGD","LU0882574055.USD","BK4139","LU0889565916.HKD","LU2362541273.HKD","LU0114720955.EUR","LU2089984988.USD","REGN","LU0289739699.SGD","BK4588","LU2237438978.USD","LU2106854487.HKD","LU0053666078.USD","LU0320765992.SGD","LU1917777945.USD","LU0823434583.USD","LU2362540622.SGD","LU0823416689.USD","LU2362541513.USD","LU0823434740.USD","LU1974910355.USD","LU0109394709.USD","LU0058720904.USD","BK4585","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642234620","title":"Parabilis Medicines Closes Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2642234620","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642234620?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:36","pubTimestamp":1781210188,"startTime":"0","endTime":"0","summary":"Parabilis Medicines (PBLS) said Thursday it has closed its upsized initial public offering of about 38.5 million shares, including the full exercise of an overallotment option, at $20.00 each.The clin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4588","IPOS","LU0823434740.USD","LU2362541273.HKD","LU1917777945.USD","LU0823434583.USD","LU0114720955.EUR","LU0289739699.SGD","LU2362540622.SGD","LU2237438978.USD","LU0053666078.USD","BK4585","LU0823416689.USD","LU2106854487.HKD","LU2362541513.USD","LU0882574055.USD","LU0320765992.SGD","LU2468319806.SGD","LU2089984988.USD","PBLS","LU0058720904.USD","REGN","BK4139","LU0109394709.USD","LU2023250504.SGD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642764064","title":"Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642764064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642764064?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:47","pubTimestamp":1781124420,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slipped 2.36% to $601.65 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 1.62% to 7,266.99 and Dow Jones Industrial Average  falling 1.87% to 49,918.78.Regeneron Pharmaceuticals Inc. closed 26.73% below its 52-week high of $821.11, which the company reached on January 9th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Amgen Inc.  fell 1.98% to $337.73, Moderna Inc.  fell 3.65% to $45.99, and Gilead Sciences Inc.  fell 3.20% to $121.48.Trading volume  remained 123,294 below its 50-day average volume of 936,592.Data source: Dow Jones Market Data, FactSet. Data compiled June 10, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478315","title":"BUZZ-Drug developer Parabilis Medicines surges in Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478315","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478315?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:19","pubTimestamp":1781111991,"startTime":"0","endTime":"0","summary":"BUZZ-Drug developer Parabilis Medicines surges in Nasdaq debut** Shares of Parabilis Medicines PBLS.O jump 43% in Nasdaq debut** The drug developer's stock opened at $33.35 apiece vs $20 IPO price** The Cambridge, Massachusetts-based PBLS sold 33.5 million shares in an upsized offering above its marketed range of $17 and $19 apiece to raise $670 million** Parabilis, whose pipeline is focused on various cancers and tumors, was co-founded in 2015 by longtime Harvard professor Greg Verdine** Separately, PBLS agreed to sell $75 million worth of shares in a concurrent private placement to Regeneron Pharmaceuticals REGN.O ** \"The upsize  a strong signal that investors are increasingly willing to fund ambitious biotechs again, especially when those companies come with external validation and a path into late-stage development\" - IPOX Research Associate Lukas Muehlbauer** \"Innovative biotech IPOs can also catch a premium with M&A remaining highly active as an important exit route for recent li","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL6N42I14U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU2362541273.HKD","LU0109394709.USD","LU0823434740.USD","LU0882574055.USD","LU2023250504.SGD","LU2089984988.USD","PBLS","LU0889565916.HKD","LU2237438978.USD","BK4139","LU0823416689.USD","BK4539","LU0058720904.USD","BK4585","REGN","LU0114720955.EUR","LU2362540622.SGD","LU0053666078.USD","LU1974910355.USD","LU0320765992.SGD","LU0823434583.USD","LU0289739699.SGD","BK4588","LU2106854487.HKD","NUVL","LU2362541513.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":-0.0228},{"period":"3month","weight":-0.1594},{"period":"6month","weight":-0.21},{"period":"1year","weight":0.1919},{"period":"ytd","weight":-0.1966}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.052257},{"month":6,"riseRate":0.444444,"avgChangeRate":0.0068},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}